Showing results (61-70 of 147) with videos related to
Sort By:
Pageof 15
Comptes Rendus Des Seances De La Societe De Biologie Et De Ses Filiales|January 1, 1975
[Effect of chronic hypoxia (Fi02 = 0.06 - Fi02 = 0.08) on mouse liver cytochrome P450 and b5 content]P Bechtel, C Delafin, Y BechtelEuropean Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|August 1, 1997
Tricyclic antidepressant-induced extrapyramidal side effectsP Vandel, B Bonin, E Leveque, et al.L'Encephale|February 11, 2000
[Abuse of tianeptine. A case report]P Vandel, W Regina, B Bonin, et al.Therapeutic Drug Monitoring|October 1, 1996
Fluoxetine addition to methadone in addicts: pharmacokinetic aspectsG Bertschy, C B Eap, K Powell, et al.Therapeutic Drug Monitoring|February 1, 1994
Probable metabolic interaction between methadone and fluvoxamine in addict patientsG Bertschy, P Baumann, C B Eap, et al.Revue Medicale Suisse|October 21, 2009
[Current topics in pharmacokinetics and pharmacogenetics of antidepressant drugs]M Gex-Fabry, G Bertschy, M Kosel, et al.Journal of Clinical Psychopharmacology|April 1, 1997
Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadoneC B Eap, G Bertschy, K Powell, et al.Pharmacopsychiatria|March 1, 1981
Clinical pharmacology of viloxazine hydrochlorideB Vandel, S Vandel, G Allers, et al.European Journal of Drug Metabolism and Pharmacokinetics|January 1, 1982
Pharmacokinetics of viloxazine hydrochloride in manB Vandel, S Vandel, J M Jounet, et al.Psychopharmacology|December 1, 1996
Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentationG Bondolfi, C Chautems, B Rochat, et al.Pageof 15